01—Abstract
Summary
Summary of the 10-K filed February 24, 2016. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc.'s 2015 10-K filing reveals a company that has successfully transitioned into an independent, global leader in animal health.
For the year ended December 31, 2015, Zoetis reported total revenue of $4.765 billiona, with a balanced contribution from its United States (49%) and International (50%) segments. The company demonstrates a strong product portfolio serving both livestock (62% of revenue) and companion animals (37% of revenue), with key product lines like ceftiofur, Revolution, and Draxxin contributing significantly to overall sales. Zoetis continues to invest in research and development, with $364 million allocated in 2015, focusing on both new product development and lifecycle innovation to maintain its competitive edge.
The company also highlights its commitment to operational efficiency, with a program aimed at simplifying its product portfolio and optimizing its supply chain. Investors should note the company's strategic acquisitions, including Pharmaq for aquaculture and assets from Abbott Animal Health to bolster its companion animal offerings.
While facing challenges such as foreign currency fluctuations (which negatively impacted revenue by 8%b in 2015) and the ongoing global economic environment, Zoetis maintains a robust liquidity position and is focused on disciplined capital allocation and long-term value creation. The company also continues to manage its relationship with Pfizer through transitional services agreements, ensuring operational continuity.
02—Key points
Key Highlights
- Total revenue of $4.765 billion for the year ended December 31, 2015.
- Balanced revenue contribution from U.S. (49%) and International (50%) segments.
- Strong product mix with 62% of revenue from Livestock and 37% from Companion Animals.
- Significant R&D investment of $364 million in 2015 to drive innovation.
- Acquisition of Pharmaq expanded presence in aquaculture, a key growth area.
- Operational efficiency program focused on portfolio simplification and supply chain optimization.
- Effective tax rate of 37.8% in 2015, impacted by various international tax considerations.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2015filed February 24, 2016Financial Statements
FY2015 against FY2014
| Line item | FY2015FY2014 | Change |
|---|---|---|
| Revenue | $4.76B$4.79B | −0.4% |
| Cost of Revenue | $1.74B$1.72B | +1.2% |
| Gross Profit | $3.03B$3.07B | −1.3% |
| SG&A Expenses | $1.53B$1.64B | −6.8% |
| Interest Expense | $124.00M$117.00M | +6.0% |
| Net Income | $339.00M$587.00M | −42.2% |
| EPS (Basic) | $0.68$1.16 | −41.4% |
| EPS (Diluted) | $0.68$1.16 | −41.4% |
| Shares Outstanding (Basic) | 499.71M501.06M | −0.3% |
| Shares Outstanding (Diluted) | 502.02M502.02M | 0.0% |
05—Questions
Frequently Asked Questions
What was Zoetis's financial performance in 2015?
For the year ended December 31, 2015, Zoetis reported total revenue of $4.765 billion. Net income attributable to Zoetis was $339 million, or $0.68 per diluted share. The company experienced an operational revenue growth of 8%, which was offset by an unfavorable foreign exchange impact of 8%, resulting in flat total revenue growth compared to 2014.
How is Zoetis diversifying its business?
Zoetis maintains a diversified business model with revenue split between Livestock (62%) and Companion Animals (37%). The company also operates in two geographic segments: the United States (49% of revenue) and International (50% of revenue). Strategic acquisitions, such as Pharmaq (aquaculture) and assets from Abbott Animal Health (companion animal surgical suite), further broaden its product portfolio and market reach.
What are the key risks identified by Zoetis in its 2015 10-K?
Key risks identified include potential restrictions and bans on the use of antibacterials in food-producing animals due to antimicrobial resistance concerns, perceived adverse effects on human health from consumption of animal products, increased regulation of the livestock industry, disease outbreaks affecting animals, customer consolidation impacting pricing power, weather and natural resource availability, global economic conditions, competition from generic products, R&D failures, and manufacturing disruptions. Foreign exchange rate fluctuations and tax-related risks were also highlighted.
What is Zoetis's approach to research and development?
Zoetis invested $364 million in R&D during 2015. The company focuses on both developing new chemical and biological entities and on product lifecycle innovation, which involves expanding claims for existing products, creating new formulations, and entering new markets. This dual approach aims to address unmet customer needs and maintain the relevance of its product lines.
06—Continue